Bone sarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bone sarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of regorafenib as maintenance treatment after first-line therapy in patients with bone sarcomas without remaining disease https://clinicaltrials.eu/trial/study-of-regorafenib-as-maintenance-treatment-after-first-line-therapy-in-patients-with-bone-sarcomas-without-remaining-disease/ Wed, 29 Apr 2026 15:08:39 +0000 https://clinicaltrials.eu/trial/study-of-regorafenib-as-maintenance-treatment-after-first-line-therapy-in-patients-with-bone-sarcomas-without-remaining-disease/ This study involves patients with bone sarcomas, which are cancers that develop in the bones. The types of bone sarcomas included in this research are osteosarcomas, Ewing sarcomas, chondrosarcomas, undifferentiated pleomorphic sarcomas, leiomyosarcomas, and angiosarcomas. The study focuses on patients who have completed their standard first-line treatment, which typically includes surgery and chemotherapy depending on the specific type of bone sarcoma, and who currently show no signs of remaining disease. The treatment being tested is regorafenib, also known by its code name BAY 73-4506, which is given as a tablet taken by mouth. This medication will be compared against placebo to see if it works better at preventing the cancer from coming back.

The purpose of this study is to determine whether regorafenib is effective as a maintenance treatment in preventing the return of bone sarcomas after patients have completed their initial treatment. Maintenance treatment means continuing therapy after the main treatment is finished to help keep the disease from coming back. The study will measure how many patients remain free from cancer recurrence at 36 months, meaning three years after starting the maintenance treatment. An event in this study would be considered any return of the cancer, whether it comes back in the original location or spreads to other parts of the body.

During the study, patients will be randomly assigned to receive either regorafenib or placebo for up to 12 months. The maximum daily dose of regorafenib that may be given is 120 milligrams. Patients will need to have regular check-ups and laboratory tests to monitor their health and check for any signs of the cancer returning. Women who can become pregnant must use birth control during treatment and for 7 months after the last dose, while men must use birth control during treatment and for 4 months after the last dose. The study will track patients over several years to see how well the treatment works in keeping the cancer from returning.

]]> Study on Sunitinib and Nivolumab with Chemotherapy for Patients with Advanced Soft Tissue and Bone Sarcomas https://clinicaltrials.eu/trial/study-on-sunitinib-and-nivolumab-with-chemotherapy-for-patients-with-advanced-soft-tissue-and-bone-sarcomas/ Wed, 29 Apr 2026 15:03:34 +0000 https://clinicaltrials.eu/trial/study-on-sunitinib-and-nivolumab-with-chemotherapy-for-patients-with-advanced-soft-tissue-and-bone-sarcomas/ This clinical trial is focused on studying treatments for advanced forms of soft tissue and bone sarcomas, which are types of cancer that develop in the body’s connective tissues, such as muscles, fat, and bones. The study is testing the effectiveness of two medications, Sutent (also known as sunitinib) and Opdivo (also known as nivolumab), both of which are used to treat certain types of cancer. Sutent is taken as a capsule, while Opdivo is given through an infusion into a vein. The trial also involves chemotherapy, which is a common cancer treatment that uses drugs to kill cancer cells.

The purpose of this study is to find the best dose of the combination of Sutent and Opdivo and to see how well this combination works in stopping the cancer from getting worse. The study is divided into different stages and groups, with some groups receiving different combinations of treatments. For example, one group will receive Sutent and Opdivo together, while another group will receive Opdivo with other chemotherapy drugs like epirubicin and ifosfamide. The study will also look at how safe these treatments are and how they affect the patients’ overall health.

Participants in the study will receive their assigned treatments and will be monitored over time to see how their cancer responds. The study aims to determine how long patients can live without their cancer getting worse and to assess the overall survival rate. The trial will also collect information on any side effects experienced by participants to ensure the treatments are as safe as possible. The study is expected to continue until 2025, with the goal of improving treatment options for people with advanced soft tissue and bone sarcomas.

]]>